NeuroBo Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

De CEO NeuroBo Pharmaceuticals is Hyung-Heon Kim, benoemd in Aug2023, heeft een ambtstermijn van 1.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.01M, bestaande uit 17.2% salaris en 82.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.32% van de aandelen van het bedrijf, ter waarde $ 64.86K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 3.3 jaar.

Belangrijke informatie

Hyung-Heon Kim

Algemeen directeur

US$1.0m

Totale compensatie

Percentage CEO-salaris	17.2%
Dienstverband CEO	1.3yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

Oct 03

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Sep 29

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

Sep 14

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

Sep 12

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

Nov 25

NeuroBo on track to post a record gain after announcing a special meeting

Jun 14

NeuroBo Pharmaceuticals rallies on ANA Therapeutics acquisition

Jan 06

Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

Dec 21

NeuroBo Pharmaceuticals EPS misses by $0.02

Nov 13

Analyse CEO-vergoeding

Hoe is Hyung-Heon Kim's beloning veranderd ten opzichte van NeuroBo Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$28m
Jun 30 2024	n/a	n/a	-US$26m
Mar 31 2024	n/a	n/a	-US$17m
Dec 31 2023	US$1m	US$174k	-US$12m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$11m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$61k	n/a	-US$14m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$14m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$29k	n/a	-US$15m

Compensatie versus markt: De totale vergoeding ($USD 1.01M ) Hyung-Heon } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 650.80K ).

Compensatie versus inkomsten: De vergoeding van Hyung-Heon is gestegen terwijl het bedrijf verliesgevend is.

CEO

Hyung-Heon Kim (49 yo)

1.3yrs

Tenure

US$1,012,073

Compensatie

Mr. Hyung-Heon Kim had been Independent Director of NeuroBo Pharmaceuticals, Inc. since July 09, 2021 until August 11, 2023 and serves as its Chief Executive Officer, President of NeuroBo Pharmaceuticals,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Hyung-Heon Kim	CEO, President & Director	1.3yrs	US$1.01m	0.32% $ 65.4k
Marshall Woodworth	Chief Financial Officer	1.1yrs	US$154.50k	geen gegevens
Mi-Kyung Kim	Chief Scientific Officer	1.3yrs	geen gegevens	geen gegevens
Robert Homolka	Senior Vice President of Clinical Operations	1.3yrs	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van NRBO wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Hyung-Heon Kim	CEO, President & Director	3.3yrs	US$1.01m	0.32% $ 65.4k
D. Strickland	Independent Director	2.8yrs	US$110.71k	0.11% $ 23.1k
Andrew Koven	Independent Chairman of the Board	3.3yrs	US$140.84k	0.11% $ 23.1k
Michael Salsbury	Independent Director	4.9yrs	US$102.36k	0.11% $ 23.1k
Roy Freeman	Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Mark Glickman	Independent Director	1.5yrs	US$50.47k	0.045% $ 9.3k
Caroline Apovian	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jason Groves	Independent Director	4.9yrs	US$100.35k	0.11% $ 23.1k
James Tursi	Independent Director	less than a year	US$21.93k	0.029% $ 5.8k
Leigh Perreault	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NRBO wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

NeuroBo Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024

NeuroBo Pharmaceuticals, Inc. Appoints James P. Tursi to its Board of Directors and as Member of Nominating and Corporate Governance Committee

NeuroBo Pharmaceuticals, Inc. Appoints Marshall H. Woodworth as Acting Chief Financial Officer

NeuroBo Pharmaceuticals, Inc. Announces Resignation of Na Yeon (Irene) Kim from the Board of Directors

NeuroBo Pharmaceuticals, Inc. Announces Executive Changes

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2023

Recent updates

New major risk - Financial position

NeuroBo Pharmaceuticals, Inc. Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

Neurobo Pharmaceuticals Announces Positive Top-Line Data from the Sad Part 1 of Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. announced that it has received $17.000005 million in funding from Dong-A ST Co., Ltd.

NeuroBo Pharmaceuticals, Inc. Doses First Patient in the MAD Part 2 of its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3.000001 million.

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024

NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals, Inc. Receives Safety Review Committee Approval to Continue with Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment

Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2A Clinical Trial Evaluating Da-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Appoints James P. Tursi to its Board of Directors and as Member of Nominating and Corporate Governance Committee

NeuroBo Pharmaceuticals, Inc. Appoints Marshall H. Woodworth as Acting Chief Financial Officer

NeuroBo Pharmaceuticals, Inc. Announces Resignation of Na Yeon (Irene) Kim from the Board of Directors

NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of Nash

NeuroBo Pharmaceuticals, Inc. Announces Executive Changes

NeuroBo Pharmaceuticals Receives 180-Day Extension to February 5, 2024 from Nasdaq to Regain Compliance with the Minimum Bid Price Requirement

Neurobo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of NASH

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2023

Neurobo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to Its Board of Directors

NeuroBo Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

NeuroBo Pharmaceuticals, Inc. Appoints Joseph Hooker as President

NeuroBo Pharmaceuticals, Inc. announced that it has received $15 million in funding from Dong-A ST Co., Ltd.

NeuroBo Pharmaceuticals Compliant with All Applicable Nasdaq Listing Criteria

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $37 million in funding from Dong-A ST Co., Ltd.

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2022

Neurobo Pharmaceuticals, Inc. Appoints Matthew Bardin as Senior Vice President Operations

High number of new and inexperienced directors

NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

No longer forecast to breakeven

Independent Director Jeong Gyun Oh has left the company

No longer forecast to breakeven

Price target decreased to US$16.00

NeuroBo Pharmaceuticals, Inc.(NasdaqCM:NRBO) dropped from Russell 3000E Index

NeuroBo on track to post a record gain after announcing a special meeting

NeuroBo Pharmaceuticals, Inc. announced delayed annual 10-K filing

NeuroBo Pharmaceuticals, Inc. Announces Board Changes

New 90-day low: US$4.68

NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding

Neurobo Pharmaceuticals, Inc. Announces Executive Changes

Neurobo Pharmaceuticals, Inc. Appoints Akash Bakshi as Class II Director to the Board and Chief Operating Officer and Senior Vice President

New 90-day high: US$6.68

NeuroBo Pharmaceuticals rallies on ANA Therapeutics acquisition

Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

NeuroBo Pharmaceuticals EPS misses by $0.02

New 90-day low: US$5.24

New 90-day low - US$5.80

New 90-day low - US$6.16

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd